FDA Approves First ctDNA-Guided Adjuvant Immunotherapy for Bladder Cancer, Rewriting the Post-Surgery Treatment Playbook

Overview

The U.S. Food and Drug Administration approved atezolizumab (Tecentriq) and its subcutaneous formulation atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) on May 15, 2026 as adjuvant treatment for adults with muscle-invasive bladder cancer after cystectomy who have circulating tumor DNA molecular residual disease, as reported by OncDaily and CancerNetwork. The agency simultaneously approved Signatera CDx (Natera, Inc.) as a companion diagnostic to identify eligible patients through blood-based ctDNA testing.

The decision marks the first time the FDA has authorized an adjuvant cancer therapy whose use is gated entirely on a molecular residual disease test rather than traditional imaging or pathological staging — a structural shift that cancer specialists say could influence how post-operative monitoring is conducted across multiple solid tumor types.

What We Know

The IMvigor011 Trial

The approval was based on data from IMvigor011 (NCT04660344), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, according to OncDaily and the Oncology Nursing Society. The trial enrolled 761 patients with muscle-invasive bladder cancer following radical cystectomy. Blood samples for ctDNA were drawn every six weeks for up to one year post-surgery, as reported by ASCO Post.

Of those 761 patients, 250 tested positive for ctDNA and were randomized 2:1 — 167 to atezolizumab and 83 to placebo. The remaining 357 patients who remained persistently ctDNA-negative received no additional treatment and were followed observationally, according to OncDaily. Results were presented by Prof. Thomas B. Powles at the ESMO Congress 2025 in Berlin and published simultaneously in the New England Journal of Medicine.

Efficacy Results

At a median follow-up of 16.1 months, atezolizumab reduced the risk of disease recurrence by 36% in ctDNA-positive patients, according to Oncozine. Median disease-free survival reached 9.9 months in the atezolizumab arm versus 4.8 months in the placebo arm (hazard ratio, 0.64; 95% CI, 0.47–0.87; P = 0.0047), as confirmed by CancerNetwork and the Oncology Nursing Society. The 12-month disease-free survival rate was 44.7% with atezolizumab versus 30.0% with placebo.

The trial also showed an improvement in overall survival, with a 41% reduction in the risk of death for atezolizumab-treated patients, per Oncozine. Median overall survival was 32.8 months with atezolizumab versus 21.1 months with placebo (HR, 0.59; 95% CI, 0.39–0.90; P = 0.0131), according to CancerNetwork. The 12-month overall survival rate was 85.1% in the atezolizumab arm versus 70.0% in the placebo arm.

The ctDNA-Negative Finding

A parallel finding from the observational arm carries its own clinical weight. Patients who remained persistently ctDNA-negative — 357 of the 761 enrolled — had a one-year disease-free survival rate of 95.4% and a two-year disease-free survival rate of 88.4% without any adjuvant treatment, according to OncDaily. At a median follow-up of 21.8 months, over 90% of ctDNA-negative patients remained alive, as reported by ASCO Post.

This finding supports a treatment de-escalation approach: patients who clear ctDNA post-surgery may be safely spared systemic therapy and its associated side effects.

Safety

Grade 3 or 4 adverse events occurred in 28% of atezolizumab-treated patients versus 22% of placebo-treated patients, per Oncozine. Fatal adverse events occurred in 3% of the atezolizumab arm (2% drug-related) versus 2% of the placebo arm. The safety profile was otherwise consistent with the known profile of atezolizumab. The FDA label includes warnings for immune-mediated adverse reactions, infusion-related reactions, hematopoietic stem cell transplant complications, and embryo-fetal toxicity, according to the Oncology Nursing Society.

What We Don’t Know

The trial’s 16.1-month median follow-up is relatively short for a disease where late recurrences are common, and the durability of the survival benefit at longer time horizons remains to be established. The study enrolled patients with high-risk muscle-invasive bladder cancer following radical cystectomy; whether the approach applies to patients with partial cystectomy or different histologies is not yet established.

It also remains unclear how broadly ctDNA-guided treatment selection will be adopted in community oncology settings, where Signatera CDx testing infrastructure may not yet be routine.

Analysis

A New Paradigm for Adjuvant Cancer Care

The IMvigor011 approval is being described by investigators as a landmark in precision oncology because it demonstrates, for the first time in a randomized phase 3 trial, that a blood-based molecular test can prospectively identify the subset of post-surgical patients who benefit from immunotherapy — and simultaneously identify those who do not need it.

Co-principal investigator Joaquim Bellmunt said: “This is the first time that an adjuvant immunotherapy trial has shown a benefit for survival in selected patients based on ctDNA testing.”

Levi Garraway, Chief Medical Officer of Roche (the maker of atezolizumab, which is marketed by Genentech in the US), noted that “serial ctDNA testing to detect molecular residual disease may advance bladder cancer treatment.”

The broader implication — that ctDNA could function as a universal gating biomarker for adjuvant immunotherapy across solid tumors — is being watched closely by oncologists working in lung, colorectal, and urothelial cancers, where post-operative surveillance and treatment selection remain active areas of controversy.

The trial was funded by F. Hoffmann-La Roche Ltd., with Natera as a collaborator providing the Signatera technology.